Zepbound (tirzepatīds) ir vienreiz nedēļā lietojams zemādas GLP-1 receptoru agonists un GIP receptoru agonists, kas paredzēts hroniskai svara kontrolei pieaugušajiem ar aptaukošanos (ĶMI ≥ 30 kg/m²) vai lieko svaru (ĶMI ≥ 27 kg/m²) un vismaz vienu ar svaru saistītu blakus slimību, piemēram, hipertensiju, 2. tipa cukura diabētu vai dislipidēmiju. Klīniskie pierādījumi rāda efektivitāti ķermeņa svara samazināšanā un kardiometabolisko parametru uzlabošanā, kombinējot ar dzīvesveida izmaiņām, tostarp kaloriju ierobežošanu un fiziskās aktivitātes palielināšanu. Zepbound ir parādījis potenciālu samazināt apnojas-hipopnojas indeksa smagumu pacientiem ar vidēji smagu līdz smagu obstruktīvu miega apnoju un vienlaicīgu aptaukošanos. Kontrindikācijas ietver vienlaicīgu lietošanu ar citām tirzepatīdu saturošām formulām vai GLP-1 receptoru agonistu medikamentiem. Bērnu drošība un efektivitāte nav noteikta. Ārstēšanu jāuzsāk un jāuzrauga kvalificētam veselības aprūpes speciālistam. Šis produkts ir paredzēts tikai pēc receptes.

To use Zepbound effectively, start with the prescribed dose, injecting once a week on the same day. Administer injections in the abdomen, thigh, or upper arm, rotating sites to avoid irritation. Before injecting, clean your hands and the injection area. Let refrigerated medication warm slightly for comfort. Use clean techniques for needle attachment and injection, disposing of sharps properly. Store the medication in the fridge or briefly at room temperature as allowed. If a dose is missed, take it soon if within a few days; otherwise, skip it and never double dose. Regularly consult with your healthcare provider to adjust doses and discuss any side effects. Always follow your healthcare provider's detailed instructions.

Tirzepatide, the active substance in Zepbound, works by mimicking the actions of natural hormones in the body that regulate blood sugar and appetite. As a dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-like Peptide-1) receptor agonist, it enhances insulin secretion in response to high blood sugar levels, slows down gastric emptying, and reduces appetite and food intake, leading to improved glycemic control and weight loss in adults with type 2 diabetes mellitus.

Gastrointestinal issues (nausea, vomiting, diarrhea, constipation), potential hypoglycemia (especially when used with other diabetes medications), injection site reactions, and possibly others depending on the individual's health condition and other medications being taken.

When using Zepbound (tirzepatide), important precautions include being vigilant for severe abdominal pain indicative of pancreatitis, monitoring blood sugar levels due to the risk of hypoglycemia when combined with other diabetes medications, reporting any changes in urination that could signal kidney issues, and seeking immediate medical attention for persistent digestive problems like vomiting or diarrhea. It's also crucial to inform your doctor of any personal or family history of thyroid cancer, given studies in rodents linking Zepbound-like medications to thyroid issues. Be alert for signs of allergic reactions, and if you're pregnant or breastfeeding, consult with your healthcare provider about potential risks.